## Index

*Note: Page numbers with f and t indicate figures and tables, respectively.*

### A

- **Action Plan on Eye Health VISION 2020 Latin America**, 140
- **Aggressive posterior retinopathy of prematurity (APROP)**, 21, 49, 82–83, 82f, 98
  - critiques and description of, 50–52
  - development of, 67–68
  - equivalent to early treatment of ROP, 52
  - mixed ROP, 63–64
  - oxygen-induced, 62–63
  - practical diagnosis and management of, 52–62
  - treatment of, 64–67
  - reactivation after, 63
  - unusual cases, 64
- **Airway management**, 135
- **Anemia**, 145
  - and erythropoietin, 5–6
- **Anesthesia for newborn**, 62. See also **Anesthesia for preterms with ROP**
- **Anesthesia for preterms with ROP**, 135
  - apnea, 135–136
    - management
      - airway management, 135
      - anesthesia management, 136–137
      - temperature management, 136
- **Angiogenesis**, 4–7
- **Anti-vascular endothelial growth factor (AntiVEGF) agents**, 89, 122–124
  - complications associated with, 124f
  - intravitreal injection of, 81
  - treatment guidelines, 87–89
  - types of, 90
- **AntiVEGF drugs, in ROP retinal detachments**, 102
  - as adjunct, 102–103
  - intravitreal corticosteroids, 103
  - plasmin, 103
  - retinal detachment after using antiVEGF drugs, 103
- **Apnea**, 135–136
- **Avascular retina**, 13, 15, 81, 83, 85, 93
- **Avastin (bevacizumab)**, 88, 90

### B

- **Benefits of Oxygen Saturation Targeting Study II (BOOST II)**, 3
- **Bevacizumab**, 65, 66, 89, 90, 123, 125
- **Bevacizumab Eliminates the Angiogenic Threat of ROP (BEAT-ROP) trial**, 7, 65, 85–86, 92
- **Bilateral retrolental fibroplasia**, 13
- **Binocular indirect ophthalmoscopy (BIO) standard**, 23
- **Bronchopulmonary dysplasia (BPD)**, 144

### C

- **Canadian Oxygen Trial (COT)**, 3
- **Candida blood cultures**, 145
- **Cardiograms**, 45
- **Choroidal circulation**, 80
- **Cicatricial contraction**, 81
- **Classical ROP (CROP)**, 49
- **Classification of ROP**, 13
  - plus disease, 17
  - Early Treatment ROP trial, 18
  - pre-threshold, 17–18
  - threshold, 18
  - stage, 15–17 (see also Stages, in classification of ROP)
  - zone, 13–15 (see also Zones, in classification of ROP)
- **Coats disease**, 130
  - retinal exudation in, 132f
- **Color Doppler OCT**, 34
- **Complications of ROP treatment**, 119
  - anti-vascular endothelial growth factor agents, 122–124
  - cryotherapy, 120–121
  - laser photocoagulation, 121–122
  - scleral buckle, 124–125
  - vitrectomy, 125–127
- **Computer-aided image analysis of the retina (CAIAR)**, 24
- **Computer-driven programs**, 45
- **Corticosteroids, intravitreal**, 103
- **Cryotherapy**, 120–121
  - complications associated with, 121f
  - laser versus, 73

© Springer International Publishing AG 2017
Andrés Kychenthal B. and Paola Dorta S. (eds.), *Retinopathy of Prematurity*, DOI 10.1007/978-3-319-52190-9
Cyclooxygenases (COX1 and COX2), 6
Cystoid macular edema (CME), 32
Cytochrome p450 monooxygenases (CYP), 6–7

D
Delayed-onset retinal detachment, 103
Differential diagnosis of ROP, 129
  clinical features, 129
  macular ectopia, 132
  retinal detachment, 130–132
  retinal fold, 132–134
  retinal ischemia, 129–130, 131f
  subretinal exudation, 130
  medical history, 129
  genetic background, 129
Digital image-handling software, 44
Doppler OCT, 34
Doppler ultrasound, 143
Dual treatment, 91

E
Early Treatment for Retinopathy of Prematurity (ETROP) study, 18, 21, 75, 84–85, 95, 107, 119
Endophthalmitis, 101–102
Endothelial nitric oxide synthetase (eNOS), 3
Epiretinal membrane (ERM), 30
Equivalent to early treatment of ROP (ETROP), 52, 66
Erythropoietin (EPO/rhEPO), 5–6, 145
Erythropoietin receptor (EPOR), 5
Experimental oxygen-induced retinopathy, phases of, 4

F
Factor X concept, 84
Familial exudative vitreoretinopathy (FEVR), 25, 46, 129–130, 130f, 133f
First epidemic of ROP, 107
Flat neovascularization, 57, 64
FocusROP program, 44, 45f, 46
Foveal vascularization, 57, 58f, 63

G
Glaucoma, 102, 126f
Glutathione (GSH), 3

H
Hand-held OCT (HHOCT) Bioptigen system, 30
High-income countries, ROP screening in, 21
High-risk pre-threshold cases, 84
Hyaloidal circulation, 80, 80f
Hyaloidal vessels, 80, 80f
Hyperoxia, 142, 143
Hypotony, 101
Hypoxia
  in complicated births, 3
  -induced pathologic neovascularization, 81f, 82f
  -inducible factor alpha 1 (HIF1α), 6

I
Ill-defined retinopathy, 50
Incontinencia pigmenti, 130
Inhalational anesthesia, 136
Injection technique, 91–92
Insulin-like growth factor (IGF-1), 4, 142
Insulin-like growth factor binding protein 3 (IGF-1BP3), 4
International Classification of Retinopathy of Prematurity (ICROP), 13, 49, 67, 68, 72
Intrauterine growth retardation (IUGR), 145
Intraventricular cerebral hemorrhage (IVH), 136
Iris and pupillary membrane vessel engorgement, 59, 60f

J
Japanese type 2 ROP, 49, 51f, 68

K
KIDROP (Karnataka Internet Assisted Diagnosis of Retinopathy of Prematurity), 23

L
Laser, 90–91, 98, 103
pharmacomodulation versus, 86–87
Laser photoacogulation, 71, 74, 75, 121–122
  in anti-VEGF area, 75–76
  complications associated with, 122f
Laser treatment, 90–91
  complications of, 74
  reactivation of ROP after, 122f, 123f
Laser versus cryotherapy, 73
Lens-sparing vitrectomy (LSV), 100
Lensectomy–vitrectomy, 100–101, 111
Light-ROP study, 8
Low- and middle-income countries, ROP screening in, 21
Lucentis (ranacizumab), 90

M
Macular ectopia, 132
Mixed ROP, 63–64
Multicenter Trial of Cryotherapy for ROP (CRYO-ROP) Study, 13, 64, 71, 83, 84, 107, 120
Mutations, 129

N
Natural history, of ROP, 21–22
Neonatal intensive care units (NICUs), 19, 23, 74
Neonatologist perspectives on ROP, 139
  newborns at risk, 144–147
  perinatal strategies in the prevention of ROP, 142
Index

perinatal strategies to be implemented, 142–143
prenatal care, 143–144
postnatal care, 143
Neovascularization, 15, 51f, 52, 54, 57, 60, 63, 64
Neovascular proliferation, 54, 60, 61f
Newborns at risk, 144–147
Nitric oxide, 3, 143–144
Nutrition, 4, 145

O
Ocriplasmin, 112
Omega-3 fatty acids, 4
Optical coherence tomography (OCT), 29–30
adaptation from adult to infant, 30–31
developmental retinal and optic nerve microanatomy observed on, 31–32
in ROP, 32–34
Optomap Panoramic 200 scanning laser ophthalmoscope (Optos P200), 35
Oxidation, inflammation, and angiogenesis, 6–7
Oxygen, 1–2
as principal risk factor, 143–144
Oxygen-induced APROP, 62–63
Oxygen-induced retinopathy (OIR), 4, 7, 8
murine model, 108
phases of, 5f
Oxygen-induced ROP (OIRROP), 57f, 61, 66
Oxygen stresses and oxidation, 2–3
Oxygen trials, 3

P
Pan American Association of Ophthalmology (PAAO), 140
Pan American Health Organization (PAHO), 140
Pars Plana Vitrectomy, 89
Pathophysiology of ROP, 1
phases of
experimental oxygen-induced retinopathy, 4
of ROP, 4
retinal vascular development, 1
role of
anemia and erythropoietin, 5–6
light, 8
oxidation, inflammation, and angiogenesis, 6–7
VEGF and angiogenesis, 4–5
term versus preterm birth, 1
nutrition, 4
oxygen, 1–2
oxygen stresses and oxidation, 2–3
oxygen trials, 3
VEGF signaling, 7
Pediatric Retinal Reading Center, 46–47
Perinatal strategies in prevention of ROP, 142
perinatal strategies to be implemented, 142–143
postnatal care, 143
advances in neonatological treatment of prematurity, 143
oxygen as principal risk factor, 143–144
ROP screening and treatment, 144
prenatal care, 142
Persistent fetal vascularization (PFV), 132
Pharmacomodulation in treatment of ROP, 79
anti-VEGF
dose, 91
current treatment guidelines, 87–89
therapy, 89
types of, 90
background of, 81
BEAT-ROP study, 85–86
CRYO-ROP study, 84
dual treatment, 91
ET-ROP study, 84–85
spontaneous regression complications, 85
injection technique, 91–92
laser, treatment with, 90–91
normal retina and vasculature, 80–81
pharmacomodulation versus laser, 86–87
ROP Crunch, 89–90
smoldering ROP, 83–84
standard versus aggressive posterior ROP, 82–83
systemic modulation in ROP, 87
treatment for typical ROP, 86
Phases of ROP, 2f, 4
Photocoagulation for ROP, 71
advantages of laser versus cryotherapy, 73
general considerations, 71–72
laser photocoagulation in anti-VEGF area, 75–76
laser treatment complications of, 74
current indications for, 72–73
performing indirect treatment for type 1 ROP, 74–75
Phospholipase A2 (PLA-2) enzymes, 6
PHOTO-ROP study, 64
Piperacaine, 92
Plasmin, 103
Plus disease, 17, 50, 52, 53f, 54f, 60f, 63
Early Treatment ROP trial, 18
pre-threshold, 17–18
threshold, 18
Portable HHOCT system, 31
Postnatal care, 143
advances in neonatological treatment of prematurity, 143
oxygen as principal risk factor, 143–144
ROP screening and treatment, 144
Prenatal care, 142
Prematurity, advances in neonatological treatment of, 143
Prematurity-related retinal detachment, 96
Prenatal care, 142
Preterinal hemorrhage after injection of bevacizumab, 124, 124f
after vitrectomy, 126, 127f
Preterm birth rates by country, 141t, 142
Pre-threshold ROP, 17–18, 85
Progression of ROP, 108, 109f
Proliferative vitreoretinopathy (PVR), 126
Prostaglandin generation, 143
Q
Quality of life, 147
Quality of ROP, 23

R
Reactivation of ROP after laser treatment, 122, 122f, 123f
Reactive nitrogen species (RNS), 3, 7
Reactive oxygen species (ROS), 3, 7
RealWorld ROP Management Programs, 23
Referral warranted ROP (RW-ROP), 36
Remote imaging for ROP screening, 43–47
RetCam 120, 35, 43
RetCam digital camera system, 17, 23, 43, 85–86
RetCam FA, 36
RETCAM imaging, 49
RETCAM retinal camera, 61
Retinal breaks, 101
Retinal detachment, 96, 103, 130–132
after using antiVEGF drugs, 103
Retinal dysplasia, 132, 133f
Retinal fold, 132–134
Retinal hypoxia, 81
Retinal Image multiScale Analysis (RISA), 24
Retinal ischemia, 129, 131f
familial exudative vitreoretinopathy, 129–130
incontinentia pigmenti, 130
shaken baby syndrome, 130
Retinal nerve fiber layer (RNFL), 30, 32
Retinal photocoagulation, 71
Retinal vascular development, 1, 80–81
Retinal vessels, 80, 80f
Retinopathy of prematurity (ROP). See individual entries, 00
Retrolental fibroplasia (RLF), 2
Revisited International Classification of Retinopathy of Prematurity (R-ICROP), 49, 50, 56, 67–68
Rhegmatogenous retinal detachment, development of, 121, 121f
ROP Crunch, 89–90, 103
ROP Tool, 24, 46
RTP801, 6

S
Scleral buckle, 99–100, 124–125
complications associated with, 125f
Screening for retinopathy of prematurity, 19, 43–47
future technology, 24–25
global selection of screening criteria, 20f
in high-income countries, 21
in low- and middle-income countries, 21
ROP natural history, 21–22
safe termination, 22–23
screening guidelines, 20–21
telemedicine approach to ROP, 23–24
time for screening, 22
Second epidemic of ROP, 107
Sevoflurane, 136
Shaken baby syndrome, 130
Shallow rhegmatogenous retinal detachment, development of, 121, 121f
Sight-threatening ROP, 21, 24, 25
Signal transducer, and activator of transcription 3 (STAT3), 5, 7
Smart software for ROP screening, 43–47
Smoldering ROP, 83–84, 91
Spectral-domain optical coherence tomography (SDOCT), 30, 32, 33f
Stage 4 ROP, management of, 95
antiVEGF drugs in retinal detachments, 102
as adjunct, 102–103
intravitreal corticosteroids, 103
plasmin, 103
retinal detachment, 103
informed consent, 97
postoperative care and follow-up, 97
preoperative examination, 97
surgical anatomy, 96
surgical team, 96
surgical techniques, 98
general aspects, 98
lens-sparing vitrectomy (LSV), 100
lensectomy–vitrectomy, 100–101
scleral buckle technique, 99–100
scleral buckling, 99
vitrectomy, 100
vitreous surgery, complications of, 101–102
timing of surgery, 97–98
Stage 5 ROP, 107
clinical course, 109–110
detachments, 108, 110
epidemiology of advanced ROP, 107–108
management, 110–112
outcomes, 112–114
pathogenesis, 108–109
screening and prevention, 114
surgical management of, 110f
vitreoretinal junction, enzymatic targeting of, 112
Stages, in classification of ROP, 15
Stage 1, 15
Stage 2, 15
Stage 3, 15
Stage 4, 15–17
Stage 5, 17
Standard versus aggressive posterior ROP, 82–83
Stratus tabletop system, 30
Subretinal exudation, 130, 132
Supplemental Therapeutic Oxygen to Prevent ROP (STOP-ROP) study, 3
Surfactant Positive Airway Pressure Pulse Oximetry Randomized Trial (SUPPORT), 3
Synergetics instrument design, 111, 111f
Systemic modulation in ROP, 87

T
Telemedicine, 23–24, 45, 146
wide field imaging and, 35–36
Temperature management, 136
Term versus preterm birth, 1
  nutrition, 4
  oxygen, 1–2
  oxygen stresses and oxidation, 2–3
  oxygen trials, 3
Tetracaine, 92
Third epidemic of ROP, 107
Threshold ROP, 18, 84, 119–120
Total hyphema after vitrectomy for ROP, 125, 125f
Trans-arachidonic acid, 7
Transient retinal vessel sheathing after injection of
  bevacizumab, 125
Trans-scleral cryotherapy, 72
Trans-scleral diode lasers, 72
Treatment for typical ROP, 86
Triamcinolone, 103
Tunica vasculosum lentis, 62, 64, 92, 108
Two-port lensectomy–vitrectomy technique, 111
Type 1/type 2 ROP, 72–73

U
Uterine artery Doppler ultrasound, 143

V
Vascular Abnormality Score on OCT (VASO), 34
Vascular Activity Score (VAS), 89
Vascular endothelial growth factor (VEGF), 6, 33, 75, 142
  and angiogenesis, 4–5
  signaling, 7
  VEGF165, 4
Vascular permeability factor (VPF), 84
Vasoproliferation, 3, 4, 6, 7, 8
Virtual Pediatric Retinal Reading Center, 46–47
Visually impaired children, 140
Vitrectomy, 100, 110
  complications associated with, 125f
  surgery, 125–127
  total hyphema after, 125f
Vitreoretinal junction, enzymatic targeting of, 112
Vitreous surgery, complications of, 101
  endophthalmitis, 101–102
  glaucoma, 102
  hemorrhage, 101
  hypotony, 101
  retinal breaks, 101

W
Wide-field fluorescein angiography, 36–37
Wide field imaging, 34–35
  and ROP telemedicine, 35–36
WINROP (Weight, IGF-1 levels, Neonatal, ROP), 25

X
X-linked FEVR, 25. See also Familial exudative vitreoretinopathy (FEVR)

Z
Zones, in classification of ROP, 13
  Zone 1, 13–14
  Zone 2, 14
  Zone 3, 14–15